During the past decade, Tennessee Oncology conducted 145 clinical trials. In the 10-year time frame, 145 clinical trials started and 48 clinical trials were completed, i.e. on average, 33.1% percent of trials that started reached the finish line to date. In the past 5 years, 83 clinical trials started and 27 clinical trials were completed. i.e. 32.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tennessee Oncology" #1 sponsor was "SCRI Development Innovations, LLC" with 39 trials, followed by "Hoffmann-La Roche" with 9 trials sponsored, "Incyte Corporation" with 8 trials sponsored, "Celgene" with 4 trials sponsored and "Clovis Oncology, Inc." with 4 trials sponsored. Other sponsors include 131 different institutions and companies that sponsored additional 102 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tennessee Oncology" #1 collaborator was "Bristol-Myers Squibb" with 10 trials as a collaborator, "Novartis" with 6 trials as a collaborator, "Genentech, Inc." with 5 trials as a collaborator, "Merck Sharp & Dohme LLC" with 5 trials as a collaborator and "Eli Lilly and Company" with 4 trials as a collaborator. Other collaborators include 70 different institutions and companies that were collaborators in the rest 59 trials.

According to Clinical.Site data, the most researched conditions in "Tennessee Oncology" are "Breast Cancer" (23 trials), "Solid Tumor" (15 trials), "Advanced Solid Tumor" (13 trials), "Colorectal Cancer" (10 trials) and "Non Small Cell Lung Cancer" (10 trials). Many other conditions were trialed in "Tennessee Oncology" in a lesser frequency.

Most popular intervention types in "Tennessee Oncology" are "Drug" (174 trials), "Biological" (20 trials), "Other" (5 trials), "Procedure" (5 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (11 trials), "Gemcitabine" (11 trials), "Atezolizumab" (10 trials), "Carboplatin" (10 trials) and "Docetaxel" (10 trials). Other intervention names were less common.

The vast majority of trials in "Tennessee Oncology" are 182 trials for "All" genders, 15 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Tennessee Oncology". undefined are not yet recruiting, 56 are recruiting, 32 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 72 completed trials in Tennessee Oncology, 2 suspended trials, and 32 terminated clinical trials to date.

Out of the total trials that were conducted in Tennessee Oncology, 95 "Phase 1" clinical trials were conducted, 114 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".

Tennessee Oncology has several departments that took part in Clinical trials: "Chattanooga Oncology Hematology Associates" - 103 trials, "Tennessee Oncology, PLLC" - 20 trials, "SCRI - Tennessee Oncology" - 42 trials, "Tennessee Oncology PLLC- Centennial Medical Center" - 19 trials, "University Oncology Associates" - 5 trials, "Tennessee Oncology, PLLC,353 New Shackle Island Road" - 4 trials, "Tennessee Oncology, PLLC,397 Wallace Road" - 4 trials, "Tennessee Oncology - Chattanooga; Tennessee Oncology - East Third Street" - 4 trials, "Tennessee Oncology, PLLC,5653 First Blvd." - 2 trials